Navigation Links
PrimeraDx Appoints Albert A. Luderer to its Board of Directors
Date:9/22/2011

MANSFIELD, Mass., Sept. 22, 2011 /PRNewswire/ -- PrimeraDx today announced that Albert Luderer has been appointed to its Board of Directors.  

President and CEO Matthew McManus commented:  "We are excited to have Al join our board at this pivotal time.  We have just launched the ICEPlex System, which is the first molecular diagnostics system that is capable of high multiplex, multi-modal qPCR, and Al brings many years of experience in the commercialization of innovative products.  Al's established track record of commercializing diagnostic technologies will provide PrimeraDx with great strategic vision as we bring personalized medicine to the clinic."

Dr. Luderer has over 30 years of leadership experience in diagnostics, therapeutics and research tools companies.  He currently serves as CEO and Board Member at Integrated Diagnostics.  Dr. Luderer has served as President, CEO, and Director at BioTrove (acquired by Life Technologies), CEO and Director of Light Sciences Inc, President and COO at bioMerieux Inc, VP of R&D and Business Development at Dianon Systems (now Lab Corp), VP of Technology Development and Support at Boehringer Mannheim (now Roche), and Head of Biomedical Research for Ciba Corning.  Dr. Luderer earned a PhD from Rutgers University.

"I am very enthusiastic about PrimeraDx and the core technology behind the ICEPlex platform.  The ability to both run a high multiplex reaction and receive a quantitative result is very timely," Commented Dr. Luderer.  "I believe that PrimeraDx is positioned to lead the next generation of molecular diagnostics technology with their all-in-one well solution."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
2. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
3. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Creabilis Appoints Dr David Roblin as Chief Medical Officer
6. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
9. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):